Methods and compositions for treating urinary incontinence using enantiomerically enriched (R)-trihexyphenidyl
AssigneeSepracor Inc.
InventorsVincent L. Fabiano, John R. McCullough
Life of this patent
Estimating the term…
Abstract
A method for treating urinary incontinence, such as incontinence resulting from bladder detrusor muscle instability, using enantiomerically enriched (R)-trihexyphenidyl. The method comprises administering a therapeutically effective amount of enantiomerically enriched (R)-trihexyphenidyl, or a pharmaceutically acceptable salt thereof, substantially free of the (S)-trihexyphenidyl enantiomer. Pharmaceutical compositions for the treatment of urinary incontinence comprising enantiomerically enriched (R)-trihexyphenidyl, or a pharmaceutically acceptable salt thereof, and an acceptable carrier are also disclosed.
Claims42
A method for treating urinary incontinence, comprising administering to a subject in need thereof a therapeutically effective amount of enantiomerically enriched (R)-trihexyphenidyl ((R)-3-(1-piperidyl)1-cyclohexyl-1-propanol), or a pharmaceutically acceptable salt thereof.
A method for treating bladder detrusor muscle instability, said method comprising administering to a subject in need thereof a therapeutically effective amount of enantiomerically enriched (R)-trihexyphenidyl, or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition, comprising enantiomerically enriched (R)-trihexyphenidyl, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
A pharmaceutical composition, comprising (R)-trihexyphenidyl, or a pharmaceutically acceptable salt thereof, substantially free of (S)-trihexyphenidyl, and a pharmaceutically acceptable carrier.
A pharmaceutical unit dosage form, which comprises enantiomerically enriched (R)-trihexyphenidyl, or a pharmaceutically acceptable salt thereof, and a pharmaceutical carrier, wherein said pharmaceutical unit dosage form is a tablet.
A pharmaceutical unit dosage form which comprises substantially enantiomerically enriched (R)-trihexyphenidyl, or a pharmaceutically acceptable salt thereof, and a pharmaceutical carrier, wherein said pharmaceutical unit dosage form is a tablet.
A pharmaceutical unit dosage form, which comprises enantiomerically enriched (R)-trihexyphenidyl, or a pharmaceutically acceptable salt thereof, and a pharmaceutical carrier, wherein said pharmaceutical unit dosage form is a soft elastic gelatin capsule.
A pharmaceutical unit dosage form which comprises substantially enantiomerically enriched (R)-trihexyphenidyl, or a pharmaceutically acceptable salt thereof, and a pharmaceutical carrier, wherein said pharmaceutical unit dosage form is a soft elastic gelatin capsule.
Enantiomerically enriched (R)-trihexyphenidyl, or a pharmaceutically acceptable salt thereof.
(R)-trihexyphenidyl, or a pharmaceutically acceptable salt thereof, substantially free of (S)-trihexyphenidyl.
A kit for treating urinary incontinence, wherein said kit comprises a pharmaceutical composition comprising enantiomerically enriched (R)-trihexyphenidyl, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, and instructions for administering said composition for treating urinary incontinence while reducing or eliminating concomitant liability of adverse effect.
A kit for treating urinary incontinence, wherein said kit comprises a pharmaceutical composition comprising substantially enantiomerically enriched (R)-trihexyphenidyl, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, and instructions for administering said composition for treating urinary incontinence while reducing or eliminating concomitant liability of adverse effects.
Dependencies are inferred from the claim text.